This Phase 2 study is designed to characterize the objective response rate (defined as
complete response (CR) and partial response (PR)) of Etirinotecan pegol administered to
subjects with metastatic and recurrent NSCLC after failure of 2nd line therapy. Up to 37
eligible subjects will receive the investigational drug q3 weeks until they are no longer
benefiting.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Etirinotecan pegol Irinotecan Topoisomerase I Inhibitors